Drug firm Lupin today said it has received final nod from the US health regulator to market its Clobetasol Propionate cream used for the treatment of various skin conditions.
The company has received final approval to market its generic Clobetasol Propionate cream USP, 0.05 per cent, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is a generic version of Fougera Pharmaceuticals Inc's Temovate cream, it added.
The cream "is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses," it added.
Shares of Lupin Ltd today closed 2.30 per cent lower at Rs 863.35 per scrip on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
